Lexicon Pharmaceuticals (NASDAQ:LXRX) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of Lexicon Pharmaceuticals (NASDAQ:LXRX) in a research note published on Wednesday morning. The firm issued a sell rating on the biopharmaceutical company’s stock.

Several other analysts also recently commented on LXRX. Needham & Company LLC reissued a “hold” rating on shares of Lexicon Pharmaceuticals in a research report on Monday, March 3rd. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price objective on shares of Lexicon Pharmaceuticals in a report on Monday, March 3rd. Leerink Partners reaffirmed a “market perform” rating and set a $1.00 price objective (down from $2.00) on shares of Lexicon Pharmaceuticals in a report on Tuesday, March 4th. Leerink Partnrs downgraded shares of Lexicon Pharmaceuticals from a “strong-buy” rating to a “hold” rating in a report on Wednesday, March 5th. Finally, Piper Sandler decreased their price objective on shares of Lexicon Pharmaceuticals from $10.00 to $6.00 and set an “overweight” rating for the company in a report on Friday, March 7th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, the stock presently has an average rating of “Hold” and a consensus price target of $3.67.

Lexicon Pharmaceuticals Stock Up 2.7 %

Lexicon Pharmaceuticals stock opened at $0.37 on Wednesday. The firm has a market cap of $90.25 million, a PE ratio of -0.49 and a beta of 1.04. The company has a debt-to-equity ratio of 0.56, a quick ratio of 7.43 and a current ratio of 7.45. The firm’s 50 day moving average price is $0.69 and its two-hundred day moving average price is $1.09. Lexicon Pharmaceuticals has a twelve month low of $0.28 and a twelve month high of $2.62.

Lexicon Pharmaceuticals (NASDAQ:LXRX) last released its quarterly earnings data on Thursday, March 6th. The biopharmaceutical company reported ($0.09) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.02. The firm had revenue of $26.55 million for the quarter, compared to analyst estimates of $6.48 million. Lexicon Pharmaceuticals had a negative net margin of 4,109.41% and a negative return on equity of 107.38%. On average, research analysts predict that Lexicon Pharmaceuticals will post -0.66 EPS for the current fiscal year.

Institutional Trading of Lexicon Pharmaceuticals

A number of hedge funds have recently bought and sold shares of LXRX. Bayesian Capital Management LP bought a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at $31,000. RPO LLC bought a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at $33,000. Renaissance Technologies LLC bought a new stake in Lexicon Pharmaceuticals in the 4th quarter valued at $38,000. Arizona State Retirement System raised its stake in shares of Lexicon Pharmaceuticals by 34.4% in the 4th quarter. Arizona State Retirement System now owns 62,976 shares of the biopharmaceutical company’s stock valued at $47,000 after buying an additional 16,136 shares in the last quarter. Finally, Teacher Retirement System of Texas raised its stake in shares of Lexicon Pharmaceuticals by 60.3% in the 4th quarter. Teacher Retirement System of Texas now owns 65,415 shares of the biopharmaceutical company’s stock valued at $48,000 after buying an additional 24,615 shares in the last quarter. 74.70% of the stock is owned by institutional investors.

About Lexicon Pharmaceuticals

Lexicon Pharmaceuticals, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain and LX2761, which is in Phase I clinical development for gastrointestinal tract.